The stock of Lyra Therapeutics Inc (NASDAQ: LYRA) has decreased by -17.82 when compared to last closing price of 0.28.Despite this, the company has seen a loss of -19.26% in its stock price over the last five trading days. zacks.com reported 2024-11-12 that Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.
Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?
The 36-month beta value for LYRA is at -0.03. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LYRA is 56.00M, and currently, shorts hold a 3.64% of that float. The average trading volume for LYRA on November 13, 2024 was 999.86K shares.
LYRA’s Market Performance
LYRA’s stock has seen a -19.26% decrease for the week, with a -1.05% drop in the past month and a -22.07% fall in the past quarter. The volatility ratio for the week is 5.67%, and the volatility levels for the past 30 days are at 8.49% for Lyra Therapeutics Inc The simple moving average for the past 20 days is -12.89% for LYRA’s stock, with a -88.48% simple moving average for the past 200 days.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at -12.02% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.67% of loss for the given period.
Volatility was left at 8.49%, however, over the last 30 days, the volatility rate increased by 5.67%, as shares sank -7.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.50% lower at present.
During the last 5 trading sessions, LYRA fell by -20.40%, which changed the moving average for the period of 200-days by -95.14% in comparison to the 20-day moving average, which settled at $0.2593. In addition, Lyra Therapeutics Inc saw -95.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -41.01 for the present operating margin
- -6.0 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -55.71. The total capital return value is set at -0.99. Equity return is now at value -156.52, with -92.07 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -2.06. The debt to equity ratio resting at 1.19. The interest coverage ratio of the stock is -69.62.
Currently, EBITDA for the company is -65.25 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 10.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.
Conclusion
In conclusion, Lyra Therapeutics Inc (LYRA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
